Pfizer at CHRNA4
As of the edition of 20 October 2026, Pfizer is on route B at CHRNA4 (neuronal acetylcholine receptor subunit alpha-4), position 4 of 2,016 on that route, with a score of 0.798.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.798
Biology proven in humans0.79
How much the company cares0.95
Room, and a reason to act now0.67
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Active at the target or its disease area recently+0.226
Took its own drug far in human testing+0.225
Few other companies active at the target+0.128
The company’s own follow-on drug+0.044
Why its own drug stopped0.000
Trials at the target more often meet than miss their main endpoint0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 26 September 2026.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 10 May 2006.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 10 May 2006.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Nicotine | Marketed | Phase 4 | 424 | none listed |
| Varenicline | Marketed | Phase 4 | 231 | none listed |
| CP-601927 | Stopped | Phase 2 | 2 | none listed |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT01396135 | CP-601927 | Phase 1 | Withdrawn | 2011 to 2011 | 0 | No results posted |
| NCT00741884 | Varenicline | Phase 2 | Withdrawn | 2010 to 2011 | 0 | No results posted |
| NCT01098240 | CP-601927 | Phase 2 | Terminated | 2010 to 2011 | 297 | No results posted |
| The registry records: “See termination reason in detailed description.” | ||||||
| NCT01574703 | Varenicline | Phase 4 | Completed | 2012 to 2015 | 4,595 | Main endpoint missed |
| NCT01312909 | Varenicline | Phase 4 | Completed | 2011 to 2018 | 312 | Main endpoint missed |
| NCT01244061 | Varenicline | Phase 4 | Completed | 2010 to 2012 | 498 | Main endpoint met |
| NCT01234142 | Varenicline | Phase 1 | Completed | 2010 to 2011 | 45 | No results posted |
| NCT01061710 | Varenicline | Completed | 2010 to 2014 | 20 | No results posted | |
| NCT01104636 | Varenicline | Completed | 2010 to 2011 | 1,177 | No results posted | |
| NCT01078298 | Varenicline | Phase 4 | Completed | 2010 to 2012 | 525 | Main endpoint met |
| NCT01013454 | Varenicline | Phase 1 | Completed | 2009 to 2009 | 12 | No results posted |
| NCT00889720 | Varenicline | Phase 4 | Completed | 2009 to 2010 | 16 | No results posted |